Dexamethasone inhibits the binding of nuclear factors to the IL-5 promoterin human CD4(+)T cells

Citation
A. Quan et al., Dexamethasone inhibits the binding of nuclear factors to the IL-5 promoterin human CD4(+)T cells, J ALLERG CL, 108(3), 2001, pp. 340-348
Citations number
35
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
ISSN journal
00916749 → ACNP
Volume
108
Issue
3
Year of publication
2001
Pages
340 - 348
Database
ISI
SICI code
0091-6749(200109)108:3<340:DITBON>2.0.ZU;2-C
Abstract
Background: IL-5 is produced by the T(H)2 subset of CD4+ T lymphocytes and is necessary for the eosinophilia typical of allergic conditions. Glucocort icoids such as dexamethasone are highly effective inhibitors of eosinophili c inflammation, and one of their effects is inhibition of IL-5 gene express ion. Objective: We wished to examine the effect of dexamethasone on the bin ding of nuclear factors from primary human CD4+ T lymphocytes to the RF-I a nd RE-II positively acting regulatory elements of the IL-5 promoter. Methods: CD4(+) T cells, purified from PBMCs by magnetic bead separation, w ere activated with anti-CD3 antibody and phorbol myristate acetate. Nuclear extracts were tested in electrophoretic mobility shift assays with probes based on RE-I and RE-II. Results: In extracts from activated cells, the RE-II region of the promoter formed a complex that was shown by supershift assay to contain NFATc. This complex was abolished by treatment of the cells with dexamethasone before activation and was weak or absent in unactivated cells. By contrast, bindin g to the RE-I region and to the GATA-3 site within RE-I was observed in res ting cells and was not affected by activation or treatment with dexamethaso ne. Conclusion: Dexamethasone inhibits the inducible binding of factors to the RE-II region but does not affect the constitutive binding to the RE-I regio n. Characterization of such molecular effects of glucocorticoids could enab le the development of specific inhibitors of IL-5 expression that lack the side effects of glucocorticolds.